Eli Lilly Daiichi Sankyo Ink Commercialization Agreement In Japan For Anti-Cgrp Antibody Galcanezumab To Treat Migraine

Eli Lilly And Daiichi Sankyo Company, Limited Have Concluded An Agreement On Commercialization Collaboration In Japan For Galcanezumab (Genetical Recombination), For Which Eli Lilly Japan Has Submitted A New Drug Application For The Treatment Of Migraine.Under The Terms Of The Agreement, Eli Lilly Japan Will Hold A Marketing Authorization For Galcanezumab And Daiichi Sankyo Will Take Charge Of Its Distribution And Sales After Marketing Approval. Both Companies Will Provide Healthcare Professionals With Information On The Drug.Through The Commercialization Collaboration With Daiichi Sankyo, Which Has A Solid Operating Foundation In Japan Based On The Established Position And Global Network In The Fields Of Central Nervous System Diseases And Pain Management, Eli Lilly Japan Will Strengthen Its System To Provide Healthcare Professionals With Proper Information On Galcanezumab After Marketing Approval.Daiichi Sankyo Will Make Efforts To Improve The Quality Of Life Of Many More Patients With Migraine By Utilizing Its Operating Foundation In Various Fields, Including The Field Of Central Nervous System Diseases In Japan, Through The Partnership With Eli Lilly Japan.Eli Lilly Japan And Daiichi Sankyo Will Closely Work Together Through The Commercialization Collaboration For Galcanezumab To Help Patients With Migraine In Japan.Galcanezumab Is A Monoclonal Antibody With A New Mode Of Action. It Binds Specifically To Calcitonin Gene-Related Peptide (Cgrp), Which Is Considered To Be Associated With Migraine, And Thereby Inhibits Binding Of Cgrp, To Its Receptor. This Drug Was Approved For The Prevention Of Migraine In September 2018 In The United States And Is Currently Used For Patients With Migraine In 20 Countries Across The World.Migraine Is A Neurological Disease Found In 3.6% Of Men And 12.9% Of Women Characterized By A Moderate To Severe Headache Synchronized With Heartbeat In One Or Both Sides Of The Head That Lasts For 4 To 72 Hours And Is Sometimes Accompanied By Other Symptoms Such As Nausea, Vomiting, And Sensitivity To Light And Sound. It Has Been Reported To Be The Second Most Disabling Disease That Affects Daily Activities Among All Diseases

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!